HUVEC/TERT662021-08-02T07:09:09+00:00

Umbilical cord

HUVEC/TERT66

Evercyte ́s human umbilical vein endothelial cell line HUVEC/TERT66 is grown continuously under xeno-free conditions while maintaining expression of cell type specific markers and functions. Therefore, these cells can be used to study vascularization in response to hypoxic conditions in tumors or ischemic tissues, to assess interaction of endothelial cells with leukocytes, macrophages or mesenchymal stem cells and to perform toxicity studies as well as to test novel compounds for pro- or anti-angiogenic activities.

General information

Cat#: CHT-006-0066

Organism: homo sapiens
Tissue, cell type: Umbilical cord, umbilical vein endothelial cells
Morphology:
endothelial morphology
Life span extension:
ectopic expression of hTERT
Quality:
free from contaminations (bacteria incl. mycoplasma, fungi, HIV, HAV, HBV, HCV, Parvo-B19) and cross-contaminations

Morphology and marker expression

HUVEC/TERT66 cells are characterized by the typical endothelial morphology and homogenous expression of cell-type specific markers such as vWF and CD31. Cell nuclei are counterstained with DAPI.

Differentiation on Matrigel and karyotype

When inoculated onto matrigel-matrix HUVEC/TERT66 cells form typical capillary like structures (left picture) demonstrating neoangiogenic potential. The cells show a normal, diploid karyotype (46, XY) as shown by COBRA FISH (right picture, kindly provided by Sheena Ong, Leiden University Medical Center).

FAQs

What is the difference between HUVEC/TERT2 and HUVEC/TERT66 cells?2021-06-21T08:34:35+00:00

HUVEC/TERT2 cells are grown in a medium containing animal-derived products (e.g. bovine brain extract and fetal bovine serum), which show high lot-to-lot variabilities. On the contrary, HUVEC/TERT66 cells are cultivated in a xeno-free medium. Therefore, HUVEC/TERT66 cells follow the current trend towards defined, xeno-free cultivation conditions, which is an essential step towards standardized cell culture.
Additionally, the growth rates differ between the two cell lines. Whereas HUVEC/TERT2 shows a population doubling time of about 28 hours, HUVEC/TERT66 cells grow significantly slower with a population doubling time of 72 hours.

In vitro propagation

Endopan 300 SL Kit (PAN Biotech) supplemented with Panexin SL-S and G418

Endopan 300 SL (PAN Biotech, Cat# P04-0065K w/o GA)

Serum substitute Panexin SL-S (PAN Biotech, Cat# P04

20 µg/ml G418 (InvivoGen, Cat# ant-gn-5)

Additional material & reagents

0,1 % Gelatin (Sigma, Cat# G1393, 2 %), diluted in PBS

Phosphate buffered saline (PBS) (Sigma, Cat# D8537)

Trypsin inhibitor (Gibco, Cat# R007100)

0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)

Protocol passaging of HUVEC/TERT66
Passaging of cells

The new culture flasks have to be pre-coated with gelatin. Therefore, the culture flasks are treated with 0.1 % gelatin solution (80 µl/cm²) at 37°C for at least 10 min (10 – 60 min). Before introducing cells, remove excess of gelatin solution.

For detachment of the cells remove and discard the culture medium and wash the cells twice with PBS (each 160 µl/cm²). Remove PBS completely.
Then, add 0.05 % Trypsin-EDTA (1x) solution (20 µl/cm²), make sure that all cells have been in contact with this solution and incubate the culture flask at 37°C for approximately 3 min.
Observe cell detachment under an inverted microscope. As soon as all cells are detached (if necessary, agitate the cells by gently hitting the flask), add Trypsin-Inhibitor (20 µl/cm²).
Thereafter, resuspend the cells in growth medium (about 160 µl/cm²) and aspirate the cells by pipetting, centrifuge at 170 g for 5 min.

Discard the supernatant, resuspend the cell pellet in the remaining droplet and add growth medium. Then, add appropriate aliquots of the cell suspension to gelatin coated culture vessels supplemented with growth medium (final volume of 240 µl/cm²).
A split ratio of 1:2 twice a week is recommended (after having reached about 90-95 % confluence).
Cultivate cells at 37°C in a humidified atmosphere with 5% CO2.

Cryopreservation

Freezing medium

CryoStor® cell cryopreservation medium CS10 (Sigma Aldrich, Cat# C2874)

Additional material & reagents

0,1 % Gelatin (Sigma, Cat# G1393, 2 %), diluted in PBS

Phosphate buffered saline (PBS) (Sigma, Cat# D8537)

0,05 % Trypsin-EDTA (Gibco, Cat# 25300-054)

Trypsin inhibitor (Gibco, Cat# R007100)

Protocol cryoprservation of HUVEC/TERT66
Freezing of cells

Detach the cells (about 90 % confluence) from the culture vessel by using Trypsin-EDTA and Trypsin-Inhibitor (Protocol passaging of HUVEC/TERT66).

Resuspend the detached cells in growth medium and centrifuge at 170 g for 5 min.
Add 1 ml of this cell suspension to each pre-cooled cryovial and immediately transfer the cells to -80°C.

After 24 hours transfer the vials to the liquid nitrogen tank.
Thawing of cells

Original Evercyte cells are to be thawed in a T25 roux flask

Before thawing the original vial containing Evercyte cells, pre-coat a 25 cm² culture flask with gelatin (Protocol passaging of HUVEC/TERT66).

Add 6 ml of complete growth medium to the pre-coated 25 cm² culture flask and place the culture flask in the incubator for at least 30 min to allow the medium to reach its normal pH.
Take a vial of frozen cells, rinse it outside with Ethanol and pre-warm in the hand until one last piece of frozen cells is seen.
Then, immediately transfer the content of the vial to a 15 ml centrifugation tube pre-filled with 9 ml of medium pre-cooled to 4°C and centrifuge for 5 min at 170 g.

Discard the supernatant and resuspend the cell pellet in the remaining droplet.

Add 1 ml of the pre-warmed medium to the cells, transfer them to the prepared culture flask and incubate at 37°C in a suitable incubator.
Perform a medium change 24 hours after thawing. If the cells are already 90 % confluent at this point, they have to be passaged.

Protocol passaging of HUVEC/TERT66

Product data sheet – certificate of analysis

Product data sheet (PDS) download
Certificate of analysis
is available upon request | Please contact us indicating the respective LOT numbers

Protocols

Preparation of HUVEC/TERT66 cell culture medium
Protocol passaging of HUVEC/TERT66
Protocol cryopreservation of HUVEC/TERT66

Data on Markers and Functions

HUVEC/TERT66 – morphology and expression of vWF and CD31
HUVEC/TERT66 – differentiation on Matrigel matrix and karyotype analysis

Safety documents (coming soon)

Telomerized human cells – material safety data sheet
HUVEC/TERT66 – cell line establishment, vector maps

Selected publications

Coming soon!

Licence Conditions

The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.

Nonprofit organizations

Evercyte grants licenses for an unlimited period to academic or nonprofit-organizations, whereby the use of Evercyte cell lines is restricted to research & development purposes and non-commercial use. The cells are not intended for human use.
The customers have to agree to the conditions described in our material transfer agreement as well as accept our general terms and conditions.
On time payment for unlimited use: EUR 1300

Profit organizations

Pharmaceutical – chemical- cosmetic industries
Evercyte grants licenses for commercial organizations, whereby we offer an initial testing phase for a flat fee that allows our customers to test our cells in their laboratories for a period of 6 months.
Thereafter, annual license fees fall due, depending on the cell line of interest. Besides offering cell lines for research & development purposes, we also have established cell factories that qualify for production of clinical grade extracellular vesicles for human application.
The customer has to agree to the conditions described in our license agreements.
Contract research organizations (CRO)
Evercyte grants licenses for contract research organizations, whereby we offer an initial testing phase for a flat fee that allows our customers to test our cells in their laboratories. Thereafter, we would negotiate a royalty based long-term license agreement individually.
The use of the cells during these phases is restricted to research & development purposes. The cells are not intended for human use. The customers have to agree to the conditions described in our material transfer agreement and accept our general terms and conditions.
Initial license fee for 6 months: EUR 2000
Annual license fee R&D: royalty based
Print Friendly, PDF & Email

from

€ 1300,–

HUVEC/TERT66
Cat#: CHT-006-0066

Ordering now

ONLY FOR NON PROFIT

Ordering

FOR PROFIT INDUSTRY

Ordering

FOR PROFIT-CRO

Related Products

umbilical vein endothelial cells

HUVEC/TERT2

read more

Related Services

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Good cell culture practice / GCCP

get ready to standardize your cell culture work

read more

news

Lecture on 3Rs

(replacement – reduction -refinement of animal experiments)

read more

services

substance testing

read more

Extracellular vesicles and angiogenesis

EVs from Wharton´s jelly-derived MSCs induce neo-angiogenesis

read more

Related Products

MyoUp MHT-040

Related Services

specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email

from

€ 1300,–

HUVEC/TERT66
Cat#: CHT-006-0066

Ordering

ONLY FOR NON PROFIT

Ordering

FOR PROFIT INDUSTRY

Ordering

FOR PROFIT-CRO

Go to Top